Feb 28, 2021
MediSieve Promoted To EIT Health Investor Network Gold Company
MediSieve has been promoted to being a Gold Company within the EIT Health Investor Network, achieving the highest possible rank.
The EIT Health Investor Network is an early stage equity funding for healthcare start-ups. The Networks connects qualified companies seeking early-stage funding with the first pan-European consortium of more than 80 investors across 18 countries. The Network helps start-ups navigate the lengthy and complex processes of raising funds, especially when launching across multiple markets in Europe. The participating investors are passionate about accelerating start-ups in order to bring innovative ideas to health markets as quickly as possible.
The Gold Label distinguishes MediSieve from the rest of participants as being a very strong project with a vast potential. The recognition will provide MediSieve with more novel mentoring and investment opportunities, allowing quicker development.
MediSieve thanks the team at EIT for all the help and support!
More about EIT:
https://eithealth.eu/programmes/investor-network/
About Magnetic Blood Filtration
MediSieve's Magnetic Blood Filtration Platform is intended to enable the rapid and specific depletion of specific agents from the bloodstream of patients. The extracorporeal therapy uses therapeutic Magnetic Beads that are designed to bind specifically to the clinical target. The Beads are introduced into the extracorporeal circuit during the therapy, mixing with the patient’s blood and binding to the clinical targets. The Delivery Platform captures all the Magnetic Beads and bound targets, preventing their return to the patient.
About MediSieve
MediSieve is a London-based BioTech start-up that has developed Magnetic Blood Filtration, a revolutionary platform therapy that enables the physical removal of specific substances from the bloodstream of patients. It can be used (1) as a direct treatment, (2) to increase the safety and efficacy of other therapies, or (3) to enable personalised medicine. The company is a spin-off from University College London and is developing its products at the White City Innovation District in West London. MediSieve is actively seeking investment and partnerships.
MEDIA CONTACT:
Alina Kagermazova
INVESTOR AND PARTNERSHIP CONTACT:
George Frodsham
